Foundation Medicine (FMI) Misses Q2 EPS by 45c

Foundation Medicine Announces 2015 Second Quarter Results and Recent Highlights

July 29, 2015 4:00 PM EDT

Year-over-Year Revenues Grow 55%; FoundationCORE Expands to More Than 50,000 Patient Cases; Guidance Updated for 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ: FMI) today reported financial and operating results for its second quarter ended June 30, 2015. Highlights for the quarter included:

8,846 clinical tests reported in the second quarter, 50% year-over-year growth; Second quarter revenue of $22.5 million, 55% year-over-year growth; Second quarter revenue from... More

Foundation Medicine Initiates Multi-Center Clinical Study Evaluating Its Circulating Tumor DNA (ctDNA) Assay in Multiple Tumor Types

July 28, 2015 6:30 AM EDT

Study Aims to Validate Assay and Identify Appropriate Clinical Subpopulations for Commercial Use

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ: FMI) today announced the initiation of a large-scale, multi-center prospective clinical study to validate its circulating tumor DNA (ctDNA) assay for multiple, solid and hematologic tumor types. Expected to launch commercially in 2016, the ctDNA assay will complement... More

University of Colorado Cancer Center and Loxo Oncology Announce Publication That Provides Clinical Validation For LOXO-101 Against TRK Fusion Cancer

July 27, 2015 3:53 PM EDT

Peer-Reviewed Research Brief Published in Cancer Discovery

First Confirmed Patient Response

AURORA, Colo. and STAMFORD, Conn., July 27, 2015 (GLOBE NEWSWIRE) -- The University of Colorado Cancer Center and Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the... More